ONC-783 for Cancer

This trial tests the safety and effectiveness of ONC-783, a new treatment for advanced cancers such as pancreatic, ovarian, colorectal, or breast cancer. As a first-phase study, researchers focus on understanding how the drug behaves in the body and its safety for patients. The trial may suit individuals diagnosed with these cancers, particularly if the cancer has spread or advanced despite previous treatments. Participants must have a measurable tumor and should not have active infections or other serious health issues that could interfere with the study. In this Phase 1 trial, participants will be among the first to receive this new treatment, contributing to crucial research on its safety and behavior in the body.

You may need to stop taking certain cancer treatments before joining the trial, as there is a required washout period (time without taking certain medications) of 21 days for most cancer drugs and 28 days for monoclonal antibody therapy. However, medications for non-cancer conditions like thyroxine, insulin, and steroid replacement are allowed.

Research shows that ONC-783 remains in the early testing stages, meaning limited information exists about its safety for people. As a Phase 1 trial, the primary goal is to assess the treatment's safety and how people's bodies respond. Phase 1 studies typically prioritize safety before evaluating the treatment's effectiveness.

Unlike the standard treatments for cancer, which often involve chemotherapy, radiation, or surgery, ONC-783 offers a new approach by being administered through a subcutaneous (SC) injection. This method might provide a more targeted and less invasive option compared to traditional therapies. Researchers are excited about ONC-783 because, as an experimental drug, it potentially introduces a novel mechanism of action that could enhance its effectiveness in treating cancer. This innovation could lead to a treatment that offers significant benefits in efficacy and patient experience over existing options.

Research shows that ONC-783 is a new treatment designed to fight cancer by targeting two proteins: CD24 on cancer cells and CD3 on T-cells, part of the immune system. This approach enhances the immune system's ability to recognize and attack cancer cells. Early results suggest that ONC-783 could treat several types of solid tumors, including colorectal, ovarian, pancreatic, and breast cancers. Although human studies provide limited information, its method of activating the immune system to combat cancer appears promising. Further research will clarify its effectiveness.¹²⁵⁶⁷